[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Jing-yuan Fang, MD, Ph. D\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":94},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,44,67],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100637262","histidine-supplementation-for-antitumor-immunity-in-colorectal-cancer-100637262",false,"NCT07577505","Histidine Supplementation for Antitumor Immunity in Colorectal Cancer","A Single-arm Clinical Study of Histidine Supplementation for Antitumor Immunity in Colorectal Cancer","Inclusion Criteria:\n\n1. Patients aged 18-80 years, regardless of sex.\n2. Body mass index (BMI) ≥18.5.\n3. NRS-2002 score \\\u003C3.\n4. Diagnosed with stage II or higher colorectal cancer who require pharmacological intervention.\n5. Capable of oral intake of medication.\n6. Willing to participate in the study and provide written informed consent.\n\nExclusion Criteria:\n\n1. Participation in other interventional clinical trials (including drugs, nutritional supplements, medical devices, etc.) within 4 weeks prior to enrollment.\n2. Presence of ascites, severe diarrhea, intractable vomiting, severe malabsorption syndrome, paralysis, mechanical intestinal obstruction, or active gastrointestinal bleeding.\n3. Allergy to sample components.\n4. Current use of other nutritional supplements that may affect the validity and effectiveness of the study results.\n5. Pregnant, lactating female patients or women with fertility who test positive in the baseline pregnancy test.\n6. Presence of cognitive impairments or mental illnesses that prevent understanding of the study procedures.\n7. Presence of any other conditions, judged by the researcher, make the participant unsuitable for participation in the study.","ALL","18 Years","80 Years",{"count":20,"type":21},20,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this clinical study is to learn whether oral histidine supplementation may be safely used to support antitumor immune function during standard colorectal cancer treatment.\n\nParticipants with colorectal cancer in the supplementation group will:\n\nTake 2g oral histidine once daily during standard colorectal cancer treatment; Provide blood samples before and after supplementation; Attend regular follow-up visits for laboratory tests, safety assessment, and treatment evaluation.",[27],"Colorectal Cancer",[27,29,30],"Histidine","Immune functions","RECRUITING","2026-08-18",{"date":34,"type":35},"2026-08-20","ACTUAL",{"date":37,"type":35},"2026-05-06",{"date":39,"type":21},"2027-06",{"name":41,"class":42},"Jing-yuan Fang, MD, Ph. D","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":54,"conditions":55,"keywords":56,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":66,"locationsCount":4},"100640648","histidine-and-immunotherapy-response-in-colorectal-cancer-100640648","NCT07586293","Histidine and Immunotherapy Response in Colorectal Cancer","Mechanistic Study of Histidine-mediated Regulation of Antigen Presentation in Colorectal Cancer to Enhance Sensitivity to Immunotherapy","Inclusion Criteria:\n\n1. Participants aged ≥18 years and ≤100 years.\n2. Patients pathologically diagnosed with colorectal cancer based on colonoscopy or surgical specimens and biopsy examination; or patients who previously received PD-1 monoclonal antibody immunotherapy for colorectal cancer.\n\nExclusion Criteria:\n\n1. Age \\\u003C18 years.\n2. Presence of poorly controlled metabolic diseases, including hypertension, diabetes mellitus, hyperlipidemia, hyperuricemia, or hyperthyroidism.\n3. Presence of other severe gastrointestinal diseases, including inflammatory bowel disease, ischemic bowel disease, familial adenomatous polyposis, liver cirrhosis, MUTYH-associated polyposis (MAP), Lynch syndrome (LS), or Peutz-Jeghers syndrome (PJS).\n4. History of other malignant tumors, or pathological diagnosis of colorectal inflammatory polyps, hyperplastic polyps, neuroendocrine tumors, neuroendocrine carcinoma, or mixed neuroendocrine-non-neuroendocrine neoplasms.\n5. History of neurological or psychiatric disorders, such as epilepsy or depression.\n6. Unqualified specimens, including hemolyzed serum samples or tissue samples that were not properly preserved in time.",{"count":52,"type":21},150,"OBSERVATIONAL","This observational study aims to investigate the role of histidine and its transporter SLC15A3 in modulating the sensitivity of colorectal cancer to immunotherapy. By analyzing the expression of SLC15A3 in tumor\u002Fnormal colonic tissues from patients with colorectal cancer and assessing serum histidine metabolic levels, the study seeks to identify potential targets associated with therapeutic resistance and explore possible intervention strategies to improve immune checkpoint blockade treatment efficacy.",[27],[57,29,58],"Colorectal cancer","immune checkpoint blockade","NOT_YET_RECRUITING","2026-05-12",{"date":62,"type":35},"2026-05-14",{"date":64,"type":21},"2026-05",{"date":39,"type":21},{"name":41,"class":42},{"id":68,"slug":69,"hasResults":11,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":4,"eligibilityCriteria":73,"healthyVolunteers":74,"sex":16,"minAge":17,"maxAge":75,"enrollmentInfo":76,"targetDuration":4,"studyType":22,"phases":77,"briefSummary":78,"conditions":79,"keywords":82,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":87,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":4},"100632899","effects-of-berberine-on-the-human-gut-microbiome-100632899","NCT07519681","Effects of Berberine on the Human Gut Microbiome","Effects of Berberine on the Human Gut Microbiome: An Exploratory Study in Healthy Volunteers and Patients With Colorectal Adenomas","Inclusion Criteria:\n\nOutpatients undergoing colonoscopy at Renji Hospital who meet the following criteria:\n\n1. Aged 18-75 years;\n2. Had at least one but no more than six histologically confirmed colorectal adenomas (including tubular, tubulovillous, and villous adenomas) removed within 6 months prior to enrollment;\n3. Provide informed consent for this study and are able to comply with the requirements for collecting qualified stool specimens, peripheral blood specimens, and providing relevant lifestyle and medical history information.\n\nHealthy subjects who meet the following criteria:\n\n1. Aged 18-75 years;\n2. Have undergone colonoscopy within 6 months prior to enrollment with no histologically confirmed colorectal adenomas (including tubular, tubulovillous, and villous adenomas);\n3. Provide informed consent for this study and are able to comply with the requirements for collecting qualified stool specimens, peripheral blood specimens, and providing relevant lifestyle and medical history information.\n\nExclusion Criteria:\n\nThe following outpatients undergoing colonoscopy at Renji Hospital:\n\n1. Incomplete resection of adenoma during colonoscopy;\n2. Individuals at high risk for hereditary colorectal cancer;\n3. Regular use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), COX-2 inhibitors, calcium, or vitamin D (defined as daily intake of ≥100 mg aspirin and ≥1200 mg calcium for at least 3 months);\n4. History of subtotal gastrectomy, total gastrectomy, or partial enterectomy;\n5. History of severe cardiac, hepatic, renal disease, or cancer;\n6. Severe constipation or psychiatric disorders;\n7. Pregnant, breastfeeding, or planning to become pregnant;\n8. Undergone colonoscopy with inadequate bowel preparation (rated as \"poor\" or \"insufficient\" according to the Aronchik scale) or short observation time (withdrawal time \\\u003C6 minutes).\n9. Use of antibiotics, probiotics, or prebiotics within 1 month prior to enrollment.\n\nThe following healthy subjects:\n\n1. Individuals at high risk for hereditary colorectal cancer;\n2. Regular use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), COX-2 inhibitors, calcium, or vitamin D (defined as daily intake of ≥100 mg aspirin and ≥1200 mg calcium for at least 3 months);\n3. History of subtotal gastrectomy, total gastrectomy, or partial enterectomy;\n4. History of severe cardiac, hepatic, renal disease, or cancer;\n5. Severe constipation or psychiatric disorders;\n6. Pregnant, breastfeeding, or planning to become pregnant;\n7. Undergone colonoscopy with inadequate bowel preparation (rated as \"poor\" or \"insufficient\" according to the Aronchik scale) or short observation time (withdrawal time \\\u003C6 minutes).\n8. Use of antibiotics, probiotics, or prebiotics within 1 month prior to enrollment.",true,"75 Years",{"count":20,"type":21},[24],"Berberine hydrochloride is a conventional component in Chinese medicine. In recent years, anticancer activity of berberine hydrochloride have been explored. The aim of this study is to investigate the effect of berberine hydrochloride on the human gut microbiome.",[80,81],"Colorectal Adenomas","Colorectal Cancers",[83,84,85,86],"colorectal adenomas","colorectal cancers","Berberine hydrochloride","human gut microbiome",{"date":88,"type":35},"2026-05-11",{"date":90,"type":21},"2026-05-15",{"date":92,"type":21},"2026-10-15",{"name":41,"class":42},""]